AA
MCID: ALP009
MIFTS: 61

Alopecia Areata (AA)

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Areata

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 75 53 25 55 6 44 15 17 72 33
Alopecia Circumscripta 53 25
Cazenave's Vitiligo 53 72
Jonston's Alopecia 53 72
Marginal Alopecia 53 72
Celsus' Vitiligo 53 72
Diffuse Alopecia 53 72
Patchy Alopecia 53 6
Alopecia Celsi 53 72
Pseudopelade 72 33
Aa 53 25
Circumscribed Alopecia 12
Alopecia Cicatrisata 53
Alopecia 72

Classifications:



External Ids:

Disease Ontology 12 DOID:986
ICD9CM 35 704.01
MeSH 44 D000506
SNOMED-CT 68 68225006
ICD10 33 L63 L63.9 L66.0
UMLS 72 C0002170 C0002171 C0086873 more

Summaries for Alopecia Areata

Genetics Home Reference : 25 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition. In most people with alopecia areata, hair falls out in small, round patches, leaving coin-sized areas of bare skin. This patchy hair loss occurs most often on the scalp but can affect other parts of the body as well. Uncommonly, the hair loss involves the entire scalp (in which case the condition is known as alopecia totalis) or the whole body (alopecia universalis). Other rare forms of alopecia areata, which have different patterns of hair loss, have also been reported. Alopecia areata affects people of all ages, although it most commonly appears in adolescence or early adulthood. Hair loss occurs over a period of weeks. The hair usually grows back after several months, although it may fall out again. In some cases, unpredictable cycles of hair loss followed by regrowth can last for years. In addition to hair loss, some affected individuals have fingernail and toenail abnormalities, such as pits on the surface of the nails. The hair loss associated with alopecia areata is not painful or disabling. However, it causes changes in a person's appearance that can profoundly affect quality of life and self-esteem. In some people, the condition can lead to depression, anxiety, and other emotional or psychological issues.

MalaCards based summary : Alopecia Areata, also known as alopecia circumscripta, is related to dermatitis, atopic and vitiligo-associated multiple autoimmune disease susceptibility 1, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is TRPS1 (Transcriptional Repressor GATA Binding 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Acitretin and fluindione have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An autoimmune hypersensitivity disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

NIH Rare Diseases : 53 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair.

Wikipedia : 75 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic 32.5 TNF IL2 IL17A IFNG ICAM1
2 vitiligo-associated multiple autoimmune disease susceptibility 1 32.4 PTPN22 CTLA4 AIRE
3 contact dermatitis 31.7 TNF IL1A IFNG ICAM1
4 thyroiditis 31.6 PTPN22 IL2 FASLG CTLA4
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.6 PTPN22 IL17A IFNG CTLA4 AIRE
6 lichen planus 31.3 TNF IFNG ICAM1 GZMB
7 candidiasis 31.3 IL17A IFNG AIRE
8 exanthem 31.2 TNF IL2 IL1RN CTLA4
9 allergic contact dermatitis 31.1 TNF IL17A IFNG ICAM1
10 autoimmune disease 31.1 TNF PTPN22 IL2RA IL2 IL17A IFNG
11 somatoform disorder 31.1 IL2RA IL1RN IL1A
12 temporal arteritis 31.1 TNF PTPN22 IL1RN IFNG
13 immune deficiency disease 31.0 IL2RA IL2 IL1A
14 juvenile rheumatoid arthritis 31.0 TNF IL2RA IL1RN
15 myasthenia gravis 31.0 TNF IL2 IFNG CTLA4 AIRE
16 skin disease 30.9 TNF IL1A IL17A IFNG ICAM1 CXCL10
17 conjunctivitis 30.9 IL2 IFNG ICAM1
18 neuritis 30.9 TNF IFNG CXCL10
19 bacterial infectious disease 30.9 TNF IL17A IFNG
20 psoriatic arthritis 30.9 TNF PTPN22 IL1A IL17A
21 tonsillitis 30.9 TNF IL2 IL1A IFNG
22 hypoadrenocorticism, familial 30.9 PTPN22 CTLA4 AIRE
23 celiac disease 1 30.8 PTPN22 KLRK1 GZMB CTLA4
24 acquired immunodeficiency syndrome 30.8 TNF IL2RA IL2 IFNG
25 lymphopenia 30.8 IL2RA IL2 IFNG FASLG
26 tetanus 30.8 IL2RA IL2 IFNG
27 cutaneous lupus erythematosus 30.8 TNF ICAM1 GZMB
28 spondylitis 30.8 TNF IL1RN IL17A
29 chronic graft versus host disease 30.8 TNF IL2RA IL1A IFNG
30 leprosy 3 30.8 TNF IL2 IFNG
31 testicular disease 30.7 TNF IL2 IFNG
32 ulcerative colitis 30.7 TNF IL2 IL17A IFNG
33 intermediate uveitis 30.6 TNF IL2RA IL2 IFNG
34 sezary's disease 30.6 IL2RA IL2 IFNG CTLA4
35 mumps 30.6 TNF IL2RA IL2 IFNG
36 sarcoidosis 1 30.6 TNF IL2RA IL2 IFNG
37 hashimoto thyroiditis 30.6 PTPN22 IL2RA IFNG ICAM1 FASLG CTLA4
38 inflammatory bowel disease 30.6 TNF IL2 IL17A IFNG
39 crohn's colitis 30.6 TNF IL2 IFNG
40 toxic shock syndrome 30.5 TNF IL2 IFNG
41 diabetes mellitus, insulin-dependent 30.5 PTPN22 IL2RA IFNG CTLA4 AIRE
42 leishmaniasis 30.5 TNF IL1A IFNG
43 graves' disease 30.5 PTPN22 IL2RA IFNG ICAM1 FASLG CTLA4
44 aggressive periodontitis 30.5 TNF IL1RN IL1A
45 periodontitis 30.4 TNF IL1A IL17A IFNG
46 osteomyelitis 30.4 TNF IL1RN IL1A IFNG
47 lymphoproliferative syndrome 30.4 IL2 FASLG CTLA4
48 keratoconjunctivitis 30.4 TNF IL2 IFNG ICAM1
49 visceral leishmaniasis 30.4 TNF IL2 IFNG
50 mycosis fungoides 30.4 IL2RA IL2 GZMB CXCL10 CTLA4

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 GZMB ICAM1 IL17A IL1A IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 GZMB ICAM1 IL17A IL1A IL2 IL2RA

MGI Mouse Phenotypes related to Alopecia Areata:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
3 digestive/alimentary MP:0005381 10.22 AIRE CTLA4 FASLG ICAM1 IFNG IL17A
4 immune system MP:0005387 10.21 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
5 cardiovascular system MP:0005385 10.19 CTLA4 CXCL10 FASLG ICAM1 IFNG IL1A
6 endocrine/exocrine gland MP:0005379 10.16 AIRE CTLA4 FASLG ICAM1 IFNG IL17A
7 mortality/aging MP:0010768 9.97 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
8 integument MP:0010771 9.92 CTLA4 FASLG ICAM1 IFNG IL1A IL1RN
9 liver/biliary system MP:0005370 9.8 AIRE CTLA4 FASLG IFNG IL2 PTPN22
10 neoplasm MP:0002006 9.5 AIRE FASLG ICAM1 IFNG IL1A IL2
11 respiratory system MP:0005388 9.32 AIRE CTLA4 FASLG IFNG IL17A IL2

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 408)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2 fluindione Approved, Investigational Phase 4 957-56-2
3
Rivaroxaban Approved Phase 4 366789-02-8
4
Phylloquinone Approved, Investigational Phase 4 84-80-0
5
Warfarin Approved Phase 4 81-81-2 6691 54678486
6
Dalteparin Approved Phase 4 9005-49-6
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
9
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
10
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13 Orange Approved Phase 4
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Drospirenone Approved Phase 4 67392-87-4 68873
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
22
Gemcitabine Approved Phase 4 95058-81-4 60750
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
25
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
26
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
27
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
28
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
29
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
32 Menaquinone Investigational Phase 4 1182-68-9
33
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
34 Emollients Phase 4
35 Anticoagulants Phase 4
36 Keratolytic Agents Phase 4
37 Serine Proteinase Inhibitors Phase 4
38 Antithrombin III Phase 4
39 Coagulants Phase 4
40 Antithrombins Phase 4
41 Antifibrinolytic Agents Phase 4
42 naphthoquinone Phase 4
43 Hemostatics Phase 4
44 Heparin, Low-Molecular-Weight Phase 4
45 Vitamin K Phase 4
46 Factor Xa Inhibitors Phase 4
47 Antivitamins K Phase 4
48 Interferon Inducers Phase 4
49 Respiratory System Agents Phase 4
50 Anti-Asthmatic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 426)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
5 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
6 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
7 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
8 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
9 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
10 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
13 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
14 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
15 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
16 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Recruiting NCT03800979 Phase 4 Tofacitinib
17 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
18 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
19 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
20 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
21 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
22 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
23 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
24 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
25 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
26 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Not yet recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
27 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
28 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
29 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
30 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
31 TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
32 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
33 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
34 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
35 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
36 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
37 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
38 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
39 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
40 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
41 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
42 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
43 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
44 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
45 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
46 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
47 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
48 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
49 Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer Completed NCT00952029 Phase 2, Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
50 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Betamethasone
Bupivacaine
D-BIOTIN
Dexamethasone
Finasteride
Minoxidil
Triamcinolone

Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Anatomical Context for Alopecia Areata

MalaCards organs/tissues related to Alopecia Areata:

41
Skin, Breast, T Cells, Ovary, Thyroid, Brain, Testes

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 3628)
# Title Authors PMID Year
1
[Regulatory effect of procyanidins on the expressions of interferon-gamma, interleukin-12 and transcription factor T-bet mRNA in peripheral blood mononuclear cell of patients with alopecia areata]. 9 38
19123327 2008
2
Immunopathogenesis of folliculitis decalvans: clues in early lesions. 9 38
18794044 2008
3
The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. 9 38
18616774 2008
4
Genetic analysis of autoimmune regulator haplotypes in alopecia areata. 9 38
18194361 2008
5
In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis. 9 38
17021766 2007
6
Investigation of the p.Ser278Arg polymorphism of the autoimmune regulator (AIRE) gene in alopecia areata. 9 38
16774540 2006
7
[Alopecia areata universalis and disseminated mollusca contagiosa in atopic dermatitis. Hair re-growth during treatment with interferon gamma--therapeutic effect or coincidence?]. 9 38
15892847 2005
8
[Interferon-gamma and neopterin in alopecia areata]. 9 38
16052058 2005
9
Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. 9 38
15037212 2004
10
The beneficial and detrimental effects of linoleic acid on autoimmune disorders. 9 38
15115315 2004
11
Interferon-gamma in alopecia areata. 9 38
14965793 2004
12
Selective expression of chemokine monokine induced by interferon-gamma in alopecia areata. 9 38
14632215 2003
13
Therapy of alopecia areata: on the cusp and in the future. 9 38
14582675 2003
14
Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. 9 38
12624779 2003
15
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. 9 38
12542742 2002
16
Epidemiology and genetics of alopecia areata. 9 38
12190641 2002
17
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction. 9 38
11841485 2002
18
Interleukin-1 receptor antagonist allele 2 and familial alopecia areata. 9 38
11841553 2002
19
Association analysis of IL1A and IL1B variants in alopecia areata. 9 38
11703512 2001
20
Role of cytotoxic T cells in chronic alopecia areata. 9 38
10620125 2000
21
Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. 9 38
10674367 1999
22
Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. 9 38
10417620 1999
23
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. 9 38
9421466 1998
24
IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha. 9 38
9266024 1997
25
Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. 9 38
8977716 1996
26
Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. 9 38
8967784 1996
27
Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. 9 38
8721483 1996
28
An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. 9 38
7738374 1995
29
Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. 9 38
8077705 1994
30
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines. 9 38
7506926 1993
31
Response of grafts from patients with alopecia areata transplanted onto nude mice, to administration of interferon-gamma. 9 38
8095867 1993
32
Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. 9 38
1708803 1991
33
JAK-inhibitors in dermatology: current evidence and future applications. 38
30433838 2019
34
A clinical and immunological study of phototoxic regimen of ultraviolet A for treatment of alopecia areata: a randomized controlled clinical trial. 38
30411986 2019
35
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. 38
29355049 2019
36
Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. 38
31048013 2019
37
Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata. 38
30513014 2019
38
Retrospective outcome analysis of 25 alopecia areata patients treated with simvastatin/ezetimibe. 38
31015012 2019
39
Regulatory T-cells in alopecia areata. 38
30989699 2019
40
Patients with alopecia areata show signs of insulin resistance. 38
31089876 2019
41
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. 38
30692587 2019
42
A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway. 38
31031313 2019
43
Identification of blood microRNA alterations in patients with severe active alopecia areata. 38
30983035 2019
44
The Association between Genetic Variation in Wnt Transcription Factor TCF7L2 (TCF4) and Alopecia Areata. 38
31012334 2019
45
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review. 38
31381252 2019
46
Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. 38
31389731 2019
47
Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico. 38
31385296 2019
48
Alopecia areata in 2 patients treated with dupilumab: New onset and worsening. 38
31388527 2019
49
Emerging Nonsteroid-Based Procedural Therapies for Alopecia Areata: A Systematic Review. 38
31403534 2019
50
Method for describing patterns and distributions of alopecia areata which may be helpful for patient characterization and predicting prognosis. 38
31215678 2019

Variations for Alopecia Areata

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TRPS1 NM_014112.5(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 8:116430587-116430587 8:115418359-115418359
2 46;XY;t(1;9;5)(compleX)dn Translocation Likely pathogenic
3 EMILIN2 ; LPIN2 ; METTL4 ; MYL12A ; MYL12B ; MYOM1 ; NDC80 ; SMCHD1 ; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance 18:1345040-3479168 :0-0

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 ULBP3 TNF PTPN22 KLRK1 IL2RA IL2
2
Show member pathways
13.68 TNF IL2RA IL2 IL1RN IL1A IL17A
3
Show member pathways
13.39 TNF IL2RA IL2 IL1A IL17A FASLG
4
Show member pathways
13.35 TNF IL2RA IL2 IL1RN IL1A IL17A
5
Show member pathways
13.3 TNF PTPN22 IL2RA IL2 IL1A IL17A
6
Show member pathways
12.7 TNF IL2RA IL2 IL1A IL17A IFNG
7
Show member pathways
12.64 TNF IL2RA IL2 IL1A IL17A IFNG
8
Show member pathways
12.6 TNF IL2 IL1A IL17A IFNG CTLA4
9
Show member pathways
12.48 ULBP3 TNF KLRK1 IL2 IFNG ICAM1
10 12.34 TNF IL2RA IL2 ICAM1
11
Show member pathways
12.33 TNF IL2 IFNG ICAM1
12
Show member pathways
12.32 TNF IL17A IFNG CXCL10
13
Show member pathways
12.3 TNF IL2RA IL2 IL1A IL17A IFNG
14
Show member pathways
12.26 TNF IL1A GZMB FASLG
15
Show member pathways
12.22 TNF IL1A IFNG FASLG
16
Show member pathways
12.19 TNF IFNG FASLG CXCL10
17
Show member pathways
12.12 IL2RA IL2 IL1A IL17A IFNG ICAM1
18 12.11 TNF IL1A IFNG ICAM1
19
Show member pathways
12.07 TNF IL2 IL17A IFNG
20 12.04 TNF KLRK1 IL2RA IL2 IFNG
21 12.02 TNF IL1A IL17A ICAM1 FASLG
22
Show member pathways
12.01 IL2RA IL2 IFNG GZMB FASLG
23 12.01 TNF IL2 IL1A IFNG ICAM1 CXCL10
24 11.88 TNF IL1A ICAM1
25 11.88 TNF IL1A IL17A IFNG ICAM1 CTLA4
26 11.88 TNF PTPN22 IL2RA IL2 IL1RN IL17A
27 11.87 TNF IL2RA IL1A
28 11.79 IL2 IFNG ICAM1
29 11.74 TNF IL2 IFNG
30
Show member pathways
11.73 TNF IL2RA IL2 IFNG FASLG CTLA4
31
Show member pathways
11.69 IL2RA IL2 FASLG
32
Show member pathways
11.69 TNF IL2 IL1A IFNG ICAM1
33 11.65 TNF IL2 IL1RN IL17A IFNG CXCL10
34 11.62 TNF IL2 IFNG FASLG
35 11.6 TNF KLRK1 IFNG ICAM1
36 11.57 TNF IL1RN IL1A ICAM1 CXCL10
37 11.55 TNF IL1A IFNG FASLG
38 11.53 TNF IL2 IFNG
39 11.51 IL2RA IL2 IFNG
40 11.49 IFNG ICAM1 FASLG
41 11.42 TNF IFNG ICAM1 FASLG
42
Show member pathways
11.42 TNF IL2RA IL2 IFNG GZMB FASLG
43 11.4 IFNG ICAM1 CXCL10
44 11.4 TNF KLRK1 IL2RA IL2 IL17A IFNG
45 11.34 IL2RA IL2 IFNG
46 11.32 TNF IL17A IFNG
47 11.29 TNF IL2 IL1A IFNG
48 11.26 IL2RA IL2 IFNG
49 11.22 TNF IL2 IL1A IL17A FASLG CXCL10
50 11.03 TNF IL2 IL1A IL17A FASLG CXCL10

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF IL2 IL1RN IL1A IL17A IFNG
2 external side of plasma membrane GO:0009897 9.23 TNF KLRK1 IL2RA IL17A ICAM1 FASLG

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 TNF IL1RN IL1A IL17A CXCL10
2 adaptive immune response GO:0002250 9.93 KLRK1 IL2 IFNG CTLA4
3 cell-cell signaling GO:0007267 9.92 IL2 IL17A FASLG CXCL10
4 response to lipopolysaccharide GO:0032496 9.87 PTPN22 ICAM1 FASLG CXCL10
5 humoral immune response GO:0006959 9.79 TNF IFNG AIRE
6 positive regulation of interferon-gamma production GO:0032729 9.72 TNF KLRK1 IL2
7 cellular response to lipopolysaccharide GO:0071222 9.72 TNF KLRK1 IL1RN ICAM1 CXCL10
8 extrinsic apoptotic signaling pathway GO:0097191 9.71 TNF IFNG FASLG
9 negative regulation of immune response GO:0050777 9.63 IL2RA CTLA4
10 natural killer cell activation GO:0030101 9.63 ULBP3 KLRK1 IL2
11 interleukin-2-mediated signaling pathway GO:0038110 9.62 IL2RA IL2
12 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL2RA IL2 IL1RN IL1A IL17A
13 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.6 TNF ICAM1
14 negative regulation of lymphocyte proliferation GO:0050672 9.59 IL2RA IL2
15 necroptotic signaling pathway GO:0097527 9.58 TNF FASLG
16 natural killer cell mediated cytotoxicity GO:0042267 9.58 ULBP3 KLRK1 GZMB
17 positive regulation of interleukin-23 production GO:0032747 9.56 IL17A IFNG
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.56 TNF KLRK1 IFNG ICAM1
19 positive regulation of osteoclast differentiation GO:0045672 9.54 TNF IL17A IFNG
20 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2RA IL2
21 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IFNG
22 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IL2 IFNG CTLA4
23 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 TNF IFNG
24 immune response GO:0006955 9.4 ULBP3 TNF IL2RA IL2 IL1RN IL1A
25 chronic inflammatory response to antigenic stimulus GO:0002439 9.21 TNF
26 apoptotic process GO:0006915 10.08 IL2RA IL1A IL17A IFNG GZMB FASLG
27 immune system process GO:0002376 10 ULBP3 PTPN22 KLRK1 IL2RA IL2 CTLA4

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 ULBP3 TRPS1 TNF PTPN22 KLRK1 IL2RA
2 cytokine activity GO:0005125 9.23 TNF IL2 IL1RN IL1A IL17A IFNG
3 interleukin-1 receptor binding GO:0005149 9.16 IL1RN IL1A

Sources for Alopecia Areata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....